A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
Public ClinicalTrials.gov record NCT02163759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
Study identification
- NCT ID
- NCT02163759
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 358 participants
Conditions and interventions
Conditions
Interventions
- Adalimumab Drug
- Adalimumab Placebo Other
- Etrolizumab Drug
- Etrolizumab Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2014
- Primary completion
- Feb 18, 2020
- Completion
- Mar 18, 2020
- Last update posted
- Jul 22, 2021
2014 – 2020
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Gastroenterology Associates, P.L.L.C.; Gastroenterology | Lakewood | Colorado | 80215 | — |
| Center for Advanced Gastroenterology | Maitland | Florida | 32751 | — |
| Gastroenterology Group of Naples | Naples | Florida | 34102 | — |
| Gastroenterology Associates of Central Georgia | Macon | Georgia | 31201 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Center for Digestive Health | Troy | Michigan | 48098 | — |
| Huron Gastroenterology Associates | Ypsilanti | Michigan | 48197 | — |
| Wellness Clinical Research Center | San Antonio | Texas | 78232 | — |
| Tyler Research Institute, LLC | Tyler | Texas | 75701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02163759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2021 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02163759 live on ClinicalTrials.gov.